Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
NCTP07250
Warning: Last items in stock!
Availability date:
DESCRIPTION | |
Species Reactivity | Human. Predicted reacts with rat, mouse. Other species not tested. |
Isotype | IgG |
Immunogen | Recombinant human PRDM1 protein 37-253bp |
Accession # | O75626 |
Alternative Names | PR domain zinc finger protein 1, BLIMP-1, Beta-interferon gene positive regulatory domain I-binding factor, PR domain-containing protein 1, PRDI-BF1, PRDI-binding factor 1, BLIMP1 |
Purification | Purified by protein affinity column. |
Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
Size | 100µg/200µl |
APPLICATION | |
ELISA | 1:20,000-1:80,000 |
Western Blot | 1:1,000-1:2,000 |
Immunohistochemistry | 1:100-1:500 |
- | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
PREPARATION AND STORAGE | |
Reconstitution | Reconstitute in 200µl of sterile H2O. |
Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
REFERENCES | |
- | Wang, X., Wang, K., Han, L., et al. PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a Dkk1-dependent manner during glioma growth. Cancer Lett. 331 (2), 211-219 (2013). |